IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Careers
    • Overview
    • Life at IMV
  • The DPX™ Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Dec 16, 2013 8:05am EST

Immunovaccine Elects Marc Mansour, Ph.D. to Board of Directors

Nov 29, 2013 8:05am EST

Immunovaccine Announces Financial Results for Quarter Ended September 30, 2013

Oct 11, 2013 4:54pm EDT

Immunovaccine Retains B & D Capital Partners For Strategic Investor Relations Services

Sep 09, 2013 8:17am EDT

Immunovaccine Reports Positive Results from Two Anthrax Studies

Sep 03, 2013 4:05pm EDT

Immunovaccine Announces Management Team Changes

Aug 29, 2013 5:05pm EDT

Immunovaccine Announces Financial Results for the Quarter Ended June 30, 2013

Aug 02, 2013 9:27am EDT

Immunovaccine Secures $5 Million Loan to Support Clinical Stage Cancer Vaccines and DepoVax(TM) Platform

Jul 15, 2013 8:05am EDT

Immunovaccine and NCIC Clinical Trials Group To Collaborate on Phase II Study of DPX-Survivac

Jun 03, 2013 8:05am EDT

Immunovaccine Shows Pronounced and Persistent T Cell Immune Responses in DPX-Survivac Cancer Vaccine Study Presented at American Society of Clinical Oncology (ASCO) Meeting

May 30, 2013 8:05am EDT

New European Phase II Trial to Test Immunovaccine's DPX-Survivac in Brain Cancer Patients

RSS
  • Prev
  • 1...
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • ...40
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us Careers The DPX™ Platform Clinical Pipeline News & Events Investors Contact
Twitter LinkedIn Youtube
© 2022 IMV Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap